Cut to the Chase™ Dating Application Brings Safe and Secure Video Chat Service to ASA Members

SYRACUSE, NY / ACCESSWIRE / January 30, 2018 / Cut to the Chase Media, Inc. is proud to announce the American Seniors Association endorsement for their innovative dating application – Cut to the Chase. The American Seniors Association selected Cut to the Chase for their members because it is the only dating app that features a video chat service where you can safely and securely meet with someone before going on an actual date.

“‘Cut to the Chase’ is the obvious choice for seniors who are looking for companionship but are uncomfortable with the notion of meeting them online,” said Stuart Barton, co-founder of American Seniors Association. “The app is so easy to use, and our seniors really feel safe knowing that they can meet with someone they are interested in – online first – from the privacy and comfort of their home – without having to and meet them in person. It removes the fear factor completely.”

Patricia Deferio, CEO and Co-Founder of Cut to the Chase, said, “This endorsement from the American Seniors Association is an important one for Cut to the Chase. The ASA reaches almost a million seniors throughout the country who may be looking to date or just for companionship.”

“As online dating has grown to be an acceptable means of meeting people, more and more people are concerned about the security of those interactions. It is important to people of all ages to make certain that you are comfortable with who you are meeting before you even leave the house. Cut to the Chase puts the control and safety of dating back in the hands of the users,” added Ms. Deferio.

With Cut to the Chase, it’s fast and easy to get started; select a few likes, take a selfie (no old high school pictures), add a 6-second video introducing yourself and you’re ready to start chasing. The app is free for all and available in the Apple App Store and Google Play.

For the first time in the world of online dating, Cut to the Chase members can meet someone who interests them – face-to-face – anonymously and securely before they invest any time or money on a first date. Even though the technology exists to facilitate peer-to-peer video calling (FaceTime, Skype, etc.), the challenge for other dating sites implementing such a feature, is maintaining and enforcing decency (inappropriate behavior), security and privacy. To keep our users safe and our platform’s reputation pure, we have implemented an inappropriate content or “panic button” technology for use by either party during a video or text chat.

The Cut to the Chase inappropriate content technology allows for the user to push a button on the device that will:

Take a screenshot of the video stream (or capture the text chat session)
Log the usernames of both participants
Log the IP address of both participants
Log the device ID for both participants
Log the date and time

The application will then package the digital assets and alert the Cut to the Chase legal team for analysis and if warranted notify the proper authorities.

“We look forward to a continuing relationship with the ASA as we strive to connect people in meaningful ways,” added Ms. Deferio.

About American Seniors Association Holding Group, Inc.

American Seniors Association Holding Group, Inc., based in Bradenton, Florida is the owner and operator of the American Seniors Association. The American Seniors Association is a conservative-oriented membership organization that offers discounted products and services to Its members throughout the United States. These services and products are offered by national and global partners such as Liberty Mutual Insurance, LifeLock, FNBO, Hertz, and Penske among others. Members receive discounts on Medicare, dental, home and auto insurance, travel discounts restaurant savings, and much more. Please visit americanseniors.org for additional information or to become a member.

About Cut to the Chase Media

Cut to the Chase Media is an innovative company that specializes in connecting people and experiences in meaningful ways. Our software and services are designed to help people connect and maintain relationships, bring together like-minded individuals, offer professional and assistive services e.g. mentoring and coaching and connect people and places for shared experiences. For more information, please visit http://cuttothechaseapp.com.

Contacts:

Cut to the Chase Media
Patricia Deferio Co-Founder and Co-CEO
315-601-4872
pat@cuttothechaseapp.com

American Seniors Association
800-951-0017
info@americanseniors.org

SOURCE: Cut to the Chase Media

ReleaseID: 487255

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage on AzurRx BioPharma, Inc. (NASDAQ: AZRX) with a 12-month price target of US $10.00.

The report is available here: AZRX Initiation Report.

We initiate coverage of AzurRx BioPharma (Nasdaq CM: AZRX, “AzurRx”) with a price target of $10.00. With headquarters in Brooklyn, NY, and scientific offices in Langlade, France, AzurRx is a clinical-stage biotechnology firm developing non-systemic, recombinant protein therapies for treatment of gastrointestinal and infectious diseases. The company’s lead candidate is MS1819, a Phase 2 autologous yeast recombinant lipase (Yarrowia lipolytica LIP2) being developed to target the $1.5 billion global market for treating Exocrine Pancreatic Insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). AzurRx’s second program is AZX1101, a pre-clinical beta-lactamase for prevention of hospital infections from resistant bacterial strains. AzurRx has several upcoming clinical events in 2018, including final data from its ongoing Phase 2 MS1819 clinical trial, initial data expected by year-end 2018 from a new Phase 2 CF trial for MS1819, and proof of concept data for AZX1101. We see the company as a speculative clinical-stage biotechnology company with an intriguing risk/reward tradeoff and several potential catalysts on the horizon.

Highlights from the report include:

Lead candidate MS1819 targeting $1.5 billion market for EPI

AzurRx is developing a portfolio with candidates addressing large market opportunities in gastrointestinal and infectious diseases. The company’s lead product candidate, MS1819 for EPI, promises significant improvements over the current standard of care, which consists of porcine pancreatic extracts (PPEs). MS1819 is designed to improve significantly the safety and efficacy of lipase substitutes for EP patients versus the standard of care – specifically in the highly acidic intestine environment – while materially reducing the patient’s pill burden. If approved, MS1819 would seek to acquire share in an existing $1.5 billion global market for treating EPI in patients with CF and CP by reducing the risk of animal viral contamination transference, improving efficacy, and significantly improving the quality of life and treatment compliance of these patients by lowering the pill burden from 25 to 40 pills per day to 5 to 8 pills per day. The company is currently conducting a Phase 2a dose escalation study of MS1819 for EPI in CP patients, and reported encouraging initial results in 3Q17; final data from the trial is expected during 2018.

AZX-1101 addresses multi-billion dollar opportunity to prevent hospital-acquired infections

AzurRx is also developing AZX1101, a pre-clinical stage recombinant-beta-lactamase combination of bacterial origin for the prevention of nosocomial (hospital-acquired) infections, such as clostridium difficile (C Diff), and antibiotic-associated diarrhea. Though in early stages of development, AZX1101 targets a significant health issue as there are 1.7mn hospital-associated infections in the United States each year with an annual cost of $4.5 billion to $10 billion annually.

Initiating coverage of AzurRx with price target of $10.00

We initiate coverage of AzurRx with a price target of $10.00. We view AzurRx as a speculative company in the biotechnology sector offering a noteworthy risk/reward tradeoff, as the company targets multi-billion dollar opportunities to treat gastrointestinal and infectious disease. AzurRx has multiple catalysts ahead as the company expects to report clinical data from Phase 2 studies of MS1819 and proof-of-concept data for AZX1101 in 2018.

Please review important disclosures on our website at www.seethruequity.com.

About AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early-stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. www.Azurrx.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high-quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit: www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 487312

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on PotNetwork Holding, Inc. (OTC PINK: POTN).

The report is available here: POTN January Update Note.

PotNetwork Holding (OTC PINK: POTN), through its subsidiary Diamond CBD Inc., focuses on research, development, and sale of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. CBD is one of the more than 85 cannabinoids identified in marijuana and hemp plants and is non-psychoactive with wide array of therapeutic benefits. Hemp derived CBDs provides a legal alternative to marijuana based CBD (which is banned at federal level) and allows the consumer to enjoy CBD without the risk of getting high and breaking any federal laws. Hemp derived CBD market is projected to grow at a CAGR of ~53% till 2020, positioning it as the fastest growing sub segment within the multi-billion-dollar legal cannabis and hemp market. Diamond CBD continues to report robust top line growth, as indicated by recent 3Q17 results and continued momentum through November. We see POTN as a speculative growth company focused on the burgeoning legal cannabis and hemp market targeting the fastest growing sub segment (hemp derived CBD). Upcoming catalysts new product launches, aggressive marketing initiatives and entry into new markets (specifically China), and efforts to uplist shares to a national market.

We are increasing our price target for POTN following strong monthly sales data and 3Q17 filings that indicate continued profitability as the company invests in growth. POTN results have included robust top line growth, with revenue already tracking above our initial estimates and company guidance. The company announced preliminary 2017E sales estimates of $14.5mn, which were in line with our recently raised estimates for 2017E, and appears well-positioned to meet or exceed our 2018E estimate, assuming continued significant sales momentum in a structural growth market.

Highlights of recent developments at POTN include:

On January 24, 2018, POTN preannounced positive full year 2017 sales results of $14.5mn, which implies sequential growth in December following sales data of “at least” $1.6mn in November.
With preliminary 2017 sales of approximately $14.5mn, POTN management appears to be executing its plan in line with our recently raised estimates, and approximately 70% higher than the initial guidance issued by the company at the beginning of the year for sales of $8.3mn.
The company now appears to be operating at an annualized revenue run rate of approximately $20mn, assuming December sales were just under $1.7mn, positioning POTN well versus our estimates of $14.5mn in 2017E and $22.8mn in 2018E.
POTN CEO Dr. Richard Goulding recently reiterated the company’s plans to uplist shares to the OTCQX, with an ultimate goal of listing on a national exchange, such as the Nasdaq CM. A national listing would likely increase liquidity and visibility for POTN. The company is preparing a Reg A filing to enable the uplisting to OTCQX.

Increasing price target to $1.25

We are increasing the target to $1.25 following recent results and share appreciation, as the company’s execution and profitability should warrant a multiple more in line with peers in the fast-growing legal cannabis market. The $1.25 target suggests a valuation of 14.7x 2018E revenues of $22.8mn and 8.2x 2019E revenues of $41.1mn.

Please review important disclosures on our website at www.seethruequity.com.

About PotNetwork Holding, Inc.

PotNetwork Holding Inc. is a publicly traded company that acts as a holding company for its subsidiary, First Capital Venture Co., the owner of Diamond CBD, Inc. Diamond CBD focuses on the research, development, and multi-national marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. For more information, visit www.diamondcbd.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high-quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit: www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 487314

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Vitality Biopharma, Inc. and updated its target price to $3.00.

The report is available here: January 2018 Update Note.

Vitality Biopharma, Inc. (OTCQB: VBIO, “Vitality”). is focused on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders. Vitality’s development pipeline is focused on a new class of cannabinoid prodrug pharmaceuticals called cannabosides. Cannabosides were discovered in 2015 through the application of the company’s proprietary enzymatic bioprocessing technologies, which were originally developed for stevia sweeteners. Cannabosides are cannabinoid glycoside “prodrugs,” which means they are medications or compounds that, after administration, are metabolized into a pharmacologically active drug. Vitality is developing cannaboside prodrugs for neurological diseases such as multiple sclerosis and inflammatory disorders, such as inflammatory bowel disease and narcotic bowel syndrome – a form of severe opiate-induced bowel dysfunction. Vitality’s lead candidates include VITA-100 for acute treatment of IBD and VITA-210, which is being investigated for chronic treatment of neuropathic pain, IBD, and muscle spasticity in multiple sclerosis.

Vitality Biopharma recently provided several investor updates with highlights including:

Vitality officially introduced VITA-100 as the company’s lead cannabinoid drug formulation. VITA-100 is a non-psychoactive, proprietary prodrug formulation of THC.

VITA-100 is a new cannabinoid prodrug called a cannaboside, which enables targeted delivery of THC to the large intestine.

THC has previously been approved by the FDA under the name dronabinol as a safe and effective means for appetite stimulation and to treat nausea.

Vitality previously announced encouraging pre-clinical data for VITA-100 showing reduced weight loss, decreased colon damage, and improved overall gastrointestinal health compared to placebo controls in a preclinical model of colitis.

The company plans to conduct its first-in-human studies in 1Q18, and is planning Phase 2 trials for inflammatory bowel syndrome (IBD), irritable bowel syndrome, and narcotic bowel syndrome – a severe form of opiate-induced pain.

These represent large market opportunities; there are approximately 1.6mn Americans living with the most common forms of IBD Crohn’s disease and colitis. Research firm Visiongain estimates the market for IBD at the company was $9.7 billion in 2017.

Vitality has applied for an Orphan Drug Designation for pediatric ulcerative colitis (UC), a chronic form of IBD which affects approximately 80,000 children in the US. If granted, would position the company for a more expedited and cost-efficient pathway for its first indication.

Increasing target to $3.00

We are updating the target to $3.00 following developmental progress made by the company including the introduction of VITA-100 for gut-targeted delivery of THC, as well as the application for an orphan drug designation for pediatric UC, which, if granted, could speed time to market and lower development costs. Upcoming catalysts include the initiation of Phase 2 human trials, which are expected to commence in 2Q18.

Please review important disclosures at www.seethruequity.com.

About Vitality Biopharma, Inc.

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. www.vitality.bio.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 487361

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / Provident Financial Holdings, Inc. (NASDAQ: PROV) will be discussing their earnings results in their Q2 Earnings Call to be held on January 30, 2018 at 12:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/1446

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 486873

VANCOUVER, BC / ACCESSWIRE / January 30, 2018 / Mezzi Holdings Inc. (“Mezzi”, or the “Company”) (TSX-V: MZI, FRA: 0MZ, OTC PINK: CCTXF) announces it has closed a tranche of its previously announced private placement (see news release dated January 3, 2018) totalling $2,696,101. These funds were raised by the Company issuing 12,255,007 units at a price of 0.22 cent per unit. Each unit consists of one common share and one half of one common share purchase warrant entitling the holder thereof to purchase one additional common share for a period of 12 months from the closing date at a price of 35 cents. The Company intends to close the balance of the financing shortly and is now in receipt of all repriced subscription agreements.

In connection with the private placement, the company paid aggregate cash commissions of $144,935.12 and issued 658,796 brokers’ warrants, each such broker’s warrant entitling the holder to acquire one common share of Mezzi at 35 cents for a period of 12 months from the closing date.

All shares, together with any shares that may be issued on exercise of the warrants and brokers’ warrants, will be subject to a hold period of 4 months from the date of issuance.

The Company intends to use the proceeds of the private placement for: (i) working capital purposes, (ii) to pursue and make an investment in the previously disclosed private company that has developed a technology which provides an auditing platform for various online transactions, and (iii) for business opportunities or investments which pertain to or enhance the company’s core business.

ON BEHALF OF THE BOARD

Keir Reynolds
Chief Executive Officer

Tel: 778-998-9242
Email: keir@dukecapitalinc.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially. There is no assurance the Company will be successful in completing its proposed private placement, or entering into any new business opportunities. The Company does not assume any obligation to update any forward-looking statements, except as required by applicable laws.

SOURCE: Mezzi Holdings Inc.

ReleaseID: 487350

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / Monro Inc (NASDAQ: MNRO) will be discussing their earnings results in their Q3 Earnings Call to be held on January 30, 2018 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/22215

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 486865

WATERLOO, ON / ACCESSWIRE / January 30, 2018 / SponsorsOne Inc. (CSE: SPO) (Frankfurt: 5SO) (the “Company”), has developed the SponsorsCloudTM platform to support the SponsorCoin, the world’s first scalable, digital cryptocurrency for social networks. Smart contracts, between brands, consumers and influencers, which automatically determine compensation for authentic social engagement are backed by SponsorCoins. SponsorsOne is pleased to announce that the SponsorsCoin digital wallet will now facilitate the automatic, real-time conversion of SponsorCoin into Bitcoin, Ethereum and many other popular cryptocurrencies that trade internationally.

“Providing liquidity outside the SponsorsCloud for our Brand Communities has always been our goal,” states Myles Bartholomew, CEO of SponsorsOne. “The conversion will be 100% cash backed and as an audited public company the cash held in reserve will be fully reported on our balance sheet.”

The SponsorCoin digital wallet will show, in real time, the exchange value of Bitcoin, Bitcoin Cash, Ethereum, Litecoin, Ripple, Dash and other currencies based on the current exchange prices around the world. With one click users can exchange their SponsorCoins into any of the supported blockchain crypto-currencies.

Each exchange is supported with USD or CAD held on SponsorsOne’s balance sheet in a segregated account and reported quarterly through an audit report. This cash reserve is built up from the revenue generated through successful marketing campaigns that lead to sales directly with brands that contract with SponsorsOne. SponsorsOne earns 20% of revenue generated from brand sales and will set aside 10% (2% of sales) of revenue as a cash reserve. Exchanged SponsorCoins will be returned back to SponsorsOne’s account for allocation back to the contracted brands supporting further smart marketing campaigns and ongoing revenue generation.

About SponsorsOne:

SponsorsOne is positioned to become a leader in the next evolution of social digital marketing and crypto-commerce with the SponsorsCloud TM platform and its highly scalable digital – smart contract based crypto-currency called SponsorCoin. Combined, this allows contracted brands to build and manage their own proprietary and highly engaged communities of influencers within the social realm. The SponsorsCloudTM platform allows for data driven marketing campaigns that will change the way brands connect to their customers and compensate the consumer for authentic engagement using the SponsorCoin digital crypto-currency. SponsorsCloud TM and SponsorsCoin are tools for brands to inspire real movements around their products and services in which their most valuable customers become their best salespeople, producing far greater ROI than current social media advertising methods.

ON BEHALF OF THE BOARD

Gary Bartholomew, Executive Chairman

To learn more please visit www.sponsorsone.com.

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this Press Release.

Forward-Looking Statements

This news release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this news release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology, are intended to identify forward-looking statements and information. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with marketing and sale of securities; the need for additional financing requirements and access to capital, reliance on key personnel; the potential for conflicts of interest among certain officers or directors with certain other projects; the volatility of the volume and price of the Common Shares, the failure of the business strategy, the integrity of the Company’s patents and proprietary intellectual property and competition. The Company cautions that the foregoing list of risk factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events, including the risk factors set out in the Company’s Listing Statement. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to above will not cause such forward-looking statements and information to differ materially from actual results or events.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE SECURITIES LEGISLATION.

SOURCE: SponsorsOne Inc.

ReleaseID: 487362

With the Star Cosmetics Nail Dryer, Polished Fingernails will Look Like they Were Professionally Manicured

LOS ANGELES, CA / ACCESSWIRE / January 30, 2018 / The founders of the Zolla company are pleased to announce the launch of the Star Cosmetics Gel UV 60w Nail Dryer on Amazon.

To check out the new nail dryer, which can be used on both fingernails and toenails, please visit https://www.amazon.com/dp/B074G4P3PH.

As a company spokesperson noted, the founders of Zolla understand that looking like a million bucks takes time and dedication. The last thing a woman wants is to spend time polishing her fingernails and/or toenails, only to have the gel polish smear and look unattractive.

“Your hands are one of the first things people notice about you. Hands are so expressive, and professionally polished nails make your hands look elegant and feminine,” the spokesperson noted.

This knowledge inspired the founders to bring the Star Cosmetics professional nail dryer to Amazon, and give women an easy and effective way to ensure their nail polish looks like it was applied at a beauty salon.

“After spreading your gel nail polish you want to make sure you have a dryer that dries instantly,” the spokesperson noted, adding that thanks to Star Cosmetics, they can use the fastest Gel dryer on the market and have a high quality and efficient product that includes auto sensors and four time interval settings of 15, 30, 60 and 90 seconds.

Using the Star Cosmetics Gel Dryer is easy; the attractive dryer, which features a lovely black and gold design, comes with a unique light that will dry the polish while protecting the hands. As a bonus, since the dryer is so small and compact, it is easy to take on the go and can be used on vacation.

Even though the Star Cosmetics Gel UV 60w Nail Dryer was only recently released on Amazon, it is already getting a lot of positive reviews from happy customers. For example, one reviewer, who bought the nail dryer for her daughter, noted that she would like to keep the Star Cosmetics dryer for herself.

“The lamp is not too hot and it dries our newly polished nails quickly,” the reviewer noted.

About the Star Cosmetics Gel UV 60w Nail Dryer:

The Zolla company is now offering the Star Cosmetics Gel UV 60w Nail Dryer on Amazon. The gel nail dryer, which can be used on fingernails and toenails, has a unique light that will quickly and efficiently dry manicures and pedicures, leaving polish looking perfect for weeks. For more information, please visit https://www.amazon.com/dp/B074G4P3PH.

Contact:

Arnold Barker
admin@rocketfactor.com
(949) 555-2861

SOURCE: Zolla

ReleaseID: 487360

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / Reinsurance Group of America, Incorporated (NYSE: RGA) will be discussing their earnings results in their Q4 Earnings Call to be held on January 30, 2018 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/1978

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 486863